Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 11/2007

01.11.2007 | Gastrointestinal Oncology

Transforming Growth Factor-β Binding Receptor Endoglin (CD105) Expression in Esophageal Cancer and in Adjacent Nontumorous Esophagus as Prognostic Predictor of Recurrence

verfasst von: Graziella Bellone, PhD, Dino Solerio, MD, Luigi Chiusa, MD, Gabriele Brondino, PhD, Anna Carbone, MSc, Adriana Prati, Tiziana Scirelli, BSc, Michele Camandona, MD, Giorgio Palestro, MD, Marcello Dei Poli, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

We hypothesized that the potent neovascularization marker endoglin (CD105), by differentially highlighting a subset of microvessels (MV) in esophageal cancer (EC), could provide better prognostic/therapeutic information than the panendothelial marker CD34, which also highlights MV.

Methods

Endoglin messenger ribonucleic acid (mRNA) expression in normal, malignant, and adjacent nontumorous esophagus tissue was quantified by real-time reverse-transcription polymerase chain reaction (RT-PCR). Sections of formalin-fixed, paraffin-embedded tissues were analyzed immunohistochemically for CD105 and CD34. MV density was counted following a standard protocol. Circulating soluble endoglin levels were determined in patient and control sera, and compared with clinical outcome.

Results

CD105 mRNA was upregulated by a median factor of 2.89 in ECs versus controls. In 28% of patients, CD105 mRNA was upregulated by a median factor of 2.65 in adjacent non-tumorous versus normal tissue. In tumor tissues, CD105 was stained negatively or positively only in a subset of MV. CD34 always showed positive extensive MV staining. In adjacent nontumorous esophagus, CD105 rarely showed diffuse MV staining, while CD34 stained blood-vessel endothelial cells in all non-neoplastic tissue. CD105 expression was high in residual highly dysplastic Barrett’s-type mucosa associated with some adenocarcinomas. No statistically significant difference in endoglin serum levels appeared between patients and normal subjects. Correlation with clinicopathological data showed higher intra-tumor MV-CD105+ scores at more-advanced clinical stages. High-scoring MV-CD105+ patients had significantly shorter disease-free and overall survival; MV-CD34+ density was not survival related. Diffuse CD105 expression in adjacent nontumorous esophagus predicted poorer disease-free and overall survival.

Conclusions

Our findings could help identify EC patients who may benefit from targeted anti-angiogenic therapies.
Literatur
1.
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6PubMedCrossRef
2.
Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 2005;54:53–61PubMedCrossRef
3.
Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 1984;49:405–13PubMed
4.
5.
Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, Dvorak HF. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305–26PubMed
6.
7.
Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2–8PubMed
8.
Tanigawa N, Matsumura M, Amaya H, et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997;79:220–5PubMedCrossRef
9.
Shimada H, Hoshino T, Okazumi S, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552–7PubMedCrossRef
10.
Kitadai Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001;93:662–6PubMedCrossRef
11.
Lord RV, Park JM, Wickramasinghe K, et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003;125:246–53PubMedCrossRef
12.
Torres C, Wang H, Turner J, Shahsafaei A, Odze RD. Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett’s esophagus-associated adenocarcinoma and squamous cell carcinoma. Hum Pathol 1999;30:753–8PubMedCrossRef
13.
Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 1999;274:584–94PubMedCrossRef
14.
Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992;267:19027–30PubMed
15.
Lastres P, Letamendia A, Zhang H, et al. Endoglin modulates cellular response to TGF-β1. J Cell Biol 1996;133:1109–21PubMedCrossRef
16.
Letamendia A, Lastres P, Botella LM, et al. Role of endoglin in cellular responses to transforming growth factor-β. J Biol Chem 1998;273:33011–9PubMedCrossRef
17.
Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81:568–72PubMedCrossRef
18.
Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004;17:197–203PubMedCrossRef
19.
Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M, Abe T. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002;131:S109–13PubMedCrossRef
20.
Yu JX, Zhang XT, Liao YQ, Zhang QY, Chen H, Lin M, Kumar S. Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol 2003;9:2866–9PubMed
21.
Dales JP, Garcia S, Andrac L, et al. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol 2004;24:1197–204PubMed
22.
Dales JP, Garcia S, Bonnier P, et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 2003;119:374–80PubMed
23.
Behrem S, Zarkovic K, Eskinja N, Jonjic N. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J 2005;46:417–22PubMed
24.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res 1998;18:1485–500PubMed
25.
Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410–5PubMed
26.
Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268–75PubMedCrossRef
27.
Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME. Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol 2000;96:224–8PubMedCrossRef
28.
Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856–61PubMed
29.
Schimming R, Marme D. Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck 2002;24:151–6PubMedCrossRef
30.
Martone T, Rosso P, Albera R, et al. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol 2005;41:147–55PubMedCrossRef
31.
Yagasaki H, Kawata N, Takimoto Y, Nemoto N. Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 2003;10:220–7PubMedCrossRef
32.
Japanese Society for Esophageal Diseases. Guide lines for the clinical and pathologic studies of the esophagus. 9th ed. Tokyo, Japan: Kanehara, 1999
33.
Lastres P, Bellon T, Cabanas C, et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992;22:393–7PubMedCrossRef
34.
Bernabeu C, Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 2003;339:62–6CrossRef
35.
Rasmussen R. Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K, (eds). Rapid Cycle Real-time PCR, Methods and Applications. Heidelberg: Springer, 2001:21–34
36.
Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36PubMedCrossRef
37.
Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8PubMedCrossRef
38.
Nakagawa S, Kitoh T. Measurement of KIT ligand/stem cell factor: clinical and biochemical significance. Curr Opin Hematol 2000;7:133–42PubMedCrossRef
39.
Abdalla SA, Behzad F, Bsharah S, Kumar S, Amini SK, O’Dwyer ST, Habaubi NY. Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 1999;6:839–42PubMed
40.
Vermeulen PB, Van den Eynden GG, Huget P, et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999;79:316–22PubMed
41.
Arakawa A, Soh S, Chakraborty S, Scardino PT, Wheeler TM. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for factor VIII-related antigen and CD34 antigen). Prostate Cancer Prostatic Dis 1997;1:32–8PubMedCrossRef
42.
Prall F, Gringmuth U, Nizze H, Barten M. Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: Significant correlation of high microvessel densities with better survival. Histopathology 2003;42:482–91PubMedCrossRef
43.
Dekel Y, Koren R, Kugel V, Livne PM, Gal R. Significance of angiogenesis and microvascular invasion in renal cell carcinoma. Pathol Oncol Res 2002;8:129–32PubMedCrossRef
44.
Pruneri G, Ponzoni M, Ferreri AJ, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002;118:817–20PubMedCrossRef
45.
Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003;22:6557–63PubMedCrossRef
46.
Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993;54:363–70PubMedCrossRef
47.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res 1998;18:1485–500PubMed
48.
Dales JP, Garcia S, Carpentier S, et al. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD 31 immunocytochemical expression. Hum Pathol 2004;35:176–83PubMedCrossRef
49.
Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Endoglin (CD 105) expression in angiogenesis of colon cancer; analysis using tissue microarrays and comparison with other endothelial markers. Vichows Arch 2005;22:1–8
50.
Santos L, Costa C, Pereira S, et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 2003;14:1419–24PubMedCrossRef
51.
Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 2005;25:201–6PubMedCrossRef
52.
Williams LJ, Guernsey DL, Casson AG. Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Curr Oncol. 2006; 13:33–43PubMed
53.
Fidler IJ, DeVita VT, Hellman S Jr, et al. (eds). Molecular biology of cancer: invasion and metastasis. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:135–52
54.
55.
Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984–92PubMedCrossRef
56.
Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524–31PubMedCrossRef
57.
58.
Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000;89:122–6PubMedCrossRef
59.
Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001;7:524–732PubMed
60.
McKian KP, Miller RC, Cassivi SD, Jatoi A. Curing patients with locally advanced esophageal cancer: an update on multimodality therapy. Dis Esophagus 2006;19:448–53PubMedCrossRef
61.
Roder JD, Busch R, Stein HJ, Fink U, Siewert JR. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410–3PubMedCrossRef
62.
Aklilu M, Ilson DH. Targeted agents and esophageal cancer–the next step? Semin Radiat Oncol 2007;17:62–9PubMedCrossRef
63.
Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999;104:1343–51PubMed
64.
Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3:1031–44PubMed
65.
Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999;5:371–82PubMed
Metadaten
Titel
Transforming Growth Factor-β Binding Receptor Endoglin (CD105) Expression in Esophageal Cancer and in Adjacent Nontumorous Esophagus as Prognostic Predictor of Recurrence
verfasst von
Graziella Bellone, PhD
Dino Solerio, MD
Luigi Chiusa, MD
Gabriele Brondino, PhD
Anna Carbone, MSc
Adriana Prati
Tiziana Scirelli, BSc
Michele Camandona, MD
Giorgio Palestro, MD
Marcello Dei Poli, MD
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9528-z

Weitere Artikel der Ausgabe 11/2007

Annals of Surgical Oncology 11/2007 Zur Ausgabe

Gastrointestinal Oncology

Short-Term Outcomes After Robotic-Assisted Total Mesorectal Excision for Rectal Cancer

Original Paper

Recurrence and Prognostic Factors of Ampullary Carcinoma after Radical Resection: Comparison with Distal Extrahepatic Cholangiocarcinoma

Editorial

DCIS of the Breast: A Look towards Discovery and Advancements in the Field

Gastrointestinal Oncology

Pneumoperitoneum in the Cancer Patient

Breast Oncology

Genomic Instability and the Development of Metastatic Lymph Node Tumors

Gastrointestinal Oncology

A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.